Rani Therapeutics has won the Presidential Poster Competition in the Bone and Mineral Metabolism category at the 105th annual meeting of The Endocrine Society (ENDO 2023) with its presentation on oral delivery of PTH for osteoporosis. The company's robotic pill, RaniPill, is designed to deliver any injectable biologic drug painlessly and is being tested as an oral alternative for a range of injection-only therapies. Rani's abstract entitled “An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers the Human Parathyroid Hormone Analog hPTH (1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study” was recognized by The Endocrine Society committee as exceptional scientific work.
The RT-102 study demonstrated that oral administration of teriparatide via RaniPill capsule was well tolerated and reliably delivered the drug with bioavailability three-to-four-fold times higher than subcutaneous injections of teriparatide. Mir Hashim, Chief Scientific Officer of Rani, said that they are honored and humbled by the recognition